Archived article
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
Pharmaceutical giant AstraZeneca reported a rise in first quarter, driven by performance in new medicines across oncology and bioPharmaceuticals.
For the first quarter of the year, revenue was up 15% to $7.32 billion as product sales increased 15% to $7.26 billion.
Oncology revenue grew 20% and new cardiovascular, renal and metabolism revenue grew 19%.
'New medicines contributed over half of revenue and all regions delivered encouraging growth,' the company said.
Covid-19 vaccine revenue was $275 million in the quarter, reflecting the delivery of 68 million doses worldwide.
The company reiterated full-year 2021 guidance for revenue to increase by a low-teens percentage, accompanied by faster growth in core EPS to $4.75 to $5.00.
'We expect the impact of COVID to reduce and anticipate a performance acceleration in the second half of 2021,' the company said.